[go: up one dir, main page]

EA201391041A1 - Растворимые в воде мембранные белки и способы их получения и применения - Google Patents

Растворимые в воде мембранные белки и способы их получения и применения

Info

Publication number
EA201391041A1
EA201391041A1 EA201391041A EA201391041A EA201391041A1 EA 201391041 A1 EA201391041 A1 EA 201391041A1 EA 201391041 A EA201391041 A EA 201391041A EA 201391041 A EA201391041 A EA 201391041A EA 201391041 A1 EA201391041 A1 EA 201391041A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
solid
production
membrane proteins
application
Prior art date
Application number
EA201391041A
Other languages
English (en)
Inventor
Шугуан Чжан
Александр Рич
Каролина Корин
Лотта Т. Теглер
Original Assignee
Массачусетс Инститьют Оф Текнолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Массачусетс Инститьют Оф Текнолоджи filed Critical Массачусетс Инститьют Оф Текнолоджи
Publication of EA201391041A1 publication Critical patent/EA201391041A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Изобретение направлено на растворимые в воде мембранные белки, способы их получения и способы их применения.
EA201391041A 2011-02-23 2012-02-23 Растворимые в воде мембранные белки и способы их получения и применения EA201391041A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161445740P 2011-02-23 2011-02-23
PCT/US2012/026353 WO2012116203A1 (en) 2011-02-23 2012-02-23 Water soluble membrane proteins and methods for the preparation and use thereof

Publications (1)

Publication Number Publication Date
EA201391041A1 true EA201391041A1 (ru) 2014-04-30

Family

ID=46721234

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391041A EA201391041A1 (ru) 2011-02-23 2012-02-23 Растворимые в воде мембранные белки и способы их получения и применения

Country Status (14)

Country Link
US (4) US8637452B2 (ru)
EP (1) EP2709647B1 (ru)
JP (1) JP6263773B2 (ru)
KR (1) KR101963914B1 (ru)
CN (2) CN103458915A (ru)
AU (3) AU2012220558A1 (ru)
BR (1) BR112013020969A2 (ru)
CA (1) CA2827187C (ru)
CL (1) CL2013002419A1 (ru)
EA (1) EA201391041A1 (ru)
IL (2) IL227886A0 (ru)
MX (1) MX347038B (ru)
SG (2) SG192646A1 (ru)
WO (1) WO2012116203A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103458915A (zh) 2011-02-23 2013-12-18 麻省理工学院 水溶性膜蛋白及其制备和使用方法
SG11201507370TA (en) 2013-03-14 2015-10-29 Massachusetts Inst Technology Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies
US9670264B2 (en) * 2013-04-25 2017-06-06 The Trustees Of The University Of Pennsylvania Water soluble G-protein coupled receptor
US10809222B2 (en) 2013-04-25 2020-10-20 The Trustees Of The University Of Pennsylvania Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor
WO2015149085A2 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015148820A1 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
GB2527286A (en) * 2014-06-11 2015-12-23 Rsr Ltd Glycoprotein hormone receptor mutations
US10961286B2 (en) 2014-08-15 2021-03-30 Cornell University Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
CN104198689A (zh) * 2014-08-25 2014-12-10 李洁 一种检测g-蛋白耦联受体对缩血管物质反应的方法
JP7061461B2 (ja) * 2015-02-18 2022-04-28 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜貫通タンパク質ならびにその調製および使用方法
CN104946674B (zh) * 2015-06-17 2018-05-01 山东大学 一种腺苷三磷酸/双磷酸酶及其编码基因与应用
CN106749602A (zh) * 2016-12-30 2017-05-31 武汉金开瑞生物工程有限公司 一种助表达序列及其在无细胞表达adcy2蛋白中的应用
WO2019046699A1 (en) * 2017-09-01 2019-03-07 Massachustetts Institute Of Technology NON-DETERGENT GPCR BIOELECTRONIC INTERFACES COUPLED TO THE 2D S-PROTEIN NETWORK, DEVICES AND METHODS OF USE THEREOF
JP7250283B2 (ja) * 2017-12-11 2023-04-03 アステラス製薬株式会社 細胞膜透過性ペプチド
CN108245686B (zh) * 2018-01-15 2019-08-13 中国科学院昆明动物研究所 人grk5基因的用途
WO2021195177A1 (en) * 2020-03-25 2021-09-30 Massachusetts Institute Of Technology Qty fc fusion water soluble receptor proteins
US11401320B2 (en) 2020-03-31 2022-08-02 Massachusetts Institute Of Technology QTY FC fusion receptor proteins
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US544021A (en) * 1895-08-06 William k
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
US5739273A (en) 1992-02-12 1998-04-14 Yale University Transmembrane polypeptide and methods of use
JPH09278793A (ja) * 1996-04-10 1997-10-28 Kinichiro Miura ポリペプチド
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CA2372164A1 (en) * 1999-03-11 2000-09-14 Gerd G. Kochendoerfer Chemical synthesis and use of soluble membrane protein receptor domains
EP1254227A2 (en) 2000-02-11 2002-11-06 Amgen Inc. Fusion receptor from tnf family
US20030143668A1 (en) * 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
EP1593060A2 (en) 2003-01-21 2005-11-09 The Trustees Of The University Of Pennsylvania Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
ATE555126T1 (de) 2004-08-25 2012-05-15 Janssen Pharmaceutica Nv Relaxin-chimere polypeptide und deren herstellung und anwendung
ATE540970T1 (de) * 2005-02-08 2012-01-15 Res Dev Foundation Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
BRPI0502759B1 (pt) * 2005-06-30 2014-02-25 óleo lubrificante e composição lubrificante para uma máquina de refrigeração
WO2007089899A2 (en) * 2006-02-01 2007-08-09 Oklahoma Medical Research Foundation Water-soluble (g protein)-coupled receptor protein
JO2968B1 (en) 2006-06-09 2016-03-15 نوفارتيس ايه جي Polypeptides are a stable insulin-like growth factor
JP4842400B2 (ja) 2007-03-22 2011-12-21 ヘプテアズ・セラピューティクス・リミテッド Ｇタンパク質共役型受容体変異体及びその選択方法
WO2008143910A2 (en) * 2007-05-18 2008-11-27 University Of Massachusetts A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
DE08718604T1 (de) 2008-03-05 2009-12-24 Medical Research Council Kristallstruktur
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
MX352415B (es) 2010-02-05 2017-11-22 Heptares Therapeutics Ltd Star Derivados de 1, 2, 4-triazin-4-amina.
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
US20140031525A1 (en) 2011-01-21 2014-01-30 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
CN103458915A (zh) 2011-02-23 2013-12-18 麻省理工学院 水溶性膜蛋白及其制备和使用方法
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US20130273585A1 (en) 2012-04-11 2013-10-17 Gangagen, Inc. Soluble cytoplasmic expression of heterologous proteins in escherichia coli
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015148820A1 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof

Also Published As

Publication number Publication date
AU2017261525A1 (en) 2017-12-07
US20180312562A1 (en) 2018-11-01
US20160264640A1 (en) 2016-09-15
CA2827187C (en) 2019-01-08
CL2013002419A1 (es) 2014-06-06
MX347038B (es) 2017-04-10
KR101963914B1 (ko) 2019-03-29
KR20140027117A (ko) 2014-03-06
US20120252719A1 (en) 2012-10-04
IL261151A (en) 2018-10-31
CN108752461A (zh) 2018-11-06
SG192646A1 (en) 2013-09-30
SG10201701547VA (en) 2017-03-30
US20140243277A1 (en) 2014-08-28
AU2016201914A1 (en) 2016-04-21
JP2014508763A (ja) 2014-04-10
JP6263773B2 (ja) 2018-01-24
US9309302B2 (en) 2016-04-12
BR112013020969A2 (pt) 2018-07-10
US10035837B2 (en) 2018-07-31
AU2012220558A1 (en) 2013-08-22
EP2709647B1 (en) 2019-08-07
MX2013009715A (es) 2014-02-28
EP2709647A4 (en) 2015-01-21
CN103458915A (zh) 2013-12-18
US8637452B2 (en) 2014-01-28
IL227886A0 (en) 2013-09-30
CA2827187A1 (en) 2012-08-30
WO2012116203A1 (en) 2012-08-30
EP2709647A1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
EA201391041A1 (ru) Растворимые в воде мембранные белки и способы их получения и применения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201391392A1 (ru) Синтетические наноносители с осмотически опосредованным высвобождением
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201300239A1 (ru) Антитела к fap и способы их применения
EA201590518A1 (ru) Стабильные водные составы адалимумаба
UY34343A (es) Proteinas de unión al antígeno cd27l
EA201400579A1 (ru) Антитела к il-36r
MX375524B (es) Anticuerpos anti-axl.
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
EA201391773A1 (ru) Клетки-предшественники мезодермальной линии
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201290642A1 (ru) Соединения и способы
MX2015012154A (es) Modulos de membrana.
ECSP13012997A (es) Antídotos anticoagulantes
EA201690263A1 (ru) Улучшенные способы получения перампанеля
EA201591725A1 (ru) Твердые липидные наночастицы (ii)
EA201500927A1 (ru) Твердые липидные наночастицы (i)